Engene Holdings Inc. (ENGN)
NASDAQ:ENGN
Want to see ENGN full AI Analyst Report?
Top Page
enGene Holdings
(NASDAQ:ENGN)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
▼(-81.41% Downside)
Action:Reiterated
Date:06/15/26
The score is held down primarily by weak financial performance (pre-revenue, widening losses, and heavy cash burn) and bearish technicals (price well below major moving averages with negative MACD). Corporate events are mixed—cost cuts may preserve runway, but the scale of restructuring and leadership changes add execution risk—while valuation provides limited support due to ongoing losses and no dividend data.
Positive Factors
Strong cash balance & low leverage
A cash position of ~$285M and historically low debt-to-equity (~0.12 TTM) provide meaningful runway for late-stage development and BLA preparation. This financial flexibility lowers immediate dilution pressure, supports regulatory interactions and pre-commercial activities, and buys time to validate pivotal data.
Negative Factors
Pre-revenue with accelerating cash burn
Persistent and growing negative operating and free cash flows mean the company remains dependent on external funding to complete pivotal work and commercial prep. Even with a strong cash balance, continued high burn raises dilution risk, can constrain strategic choices, and increases execution pressure to demonstrate clinical success quickly.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong cash balance & low leverage
A cash position of ~$285M and historically low debt-to-equity (~0.12 TTM) provide meaningful runway for late-stage development and BLA preparation. This financial flexibility lowers immediate dilution pressure, supports regulatory interactions and pre-commercial activities, and buys time to validate pivotal data.
Read all positive factors
enGene Holdings (ENGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$118.57M
Dividend YieldN/A
Average Volume (3M)2.92M
Price to Earnings (P/E)―
Beta (1Y)0.50
Revenue GrowthN/A
EPS Growth-32.34%
CountryUS
Employees56
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.32
Shares Outstanding66,989,460
10 Day Avg. Volume853,525
30 Day Avg. Volume2,923,855
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.20
Price to Sales (P/S)0.00
P/FCF Ratio-3.66
Enterprise Value/Market Cap0.57
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-182.93
Enterprise Value/Ebitda-0.54
Forecast
1Y Price Target
$3.00Price Target Upside-62.83% Downside
Rating ConsensusHold
Number of Analyst Covering10
EPS Forecast (FY)-1.97
Revenue Forecast (FY)N/A
enGene Holdings Business Overview & Revenue Model
Company Description
Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal t...
How the Company Makes Money
null...
enGene Holdings Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
62
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -369.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -125.94M | -113.80M | -52.04M | -94.77M | -22.78M | -18.14M |
| Net Income | -66.40M | -117.30M | -55.14M | -99.92M | -24.46M | -23.44M |
Balance Sheet | ||||||
| Total Assets | 307.52M | 221.47M | 311.17M | 86.96M | 132.04M | 131.45M |
| Cash, Cash Equivalents and Short-Term Investments | 258.46M | 193.81M | 238.40M | 81.60M | 314.15K | 1.07M |
| Total Debt | 8.25M | 31.80M | 25.02M | 9.78M | 32.11M | 4.16M |
| Total Liabilities | 52.36M | 53.76M | 38.56M | 14.47M | 4.62M | 4.05M |
| Stockholders Equity | 255.17M | 167.71M | 272.61M | 72.49M | 127.42M | 127.39M |
Cash Flow | ||||||
| Free Cash Flow | -111.39M | -100.72M | -49.21M | -25.06M | -17.75M | -16.23M |
| Operating Cash Flow | -110.00M | -99.24M | -48.28M | -24.74M | -17.59M | -15.98M |
| Investing Cash Flow | -60.78M | -25.14M | -125.95M | -318.00K | -153.00K | -247.00K |
| Financing Cash Flow | 143.06M | 1.52M | 265.72M | 86.15M | 27.97M | 22.52M |
enGene Holdings Technical Analysis
Neutral
8.07
Price Trends
4.33
Negative
6.55
Negative
7.13
Negative
Market Momentum
-0.63
Negative
33.64
Neutral
58.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENGN, the sentiment is Neutral. The current price of 8.07 is above the 20-day moving average (MA) of 1.69, above the 50-day MA of 4.33, and above the 200-day MA of 7.13, indicating a neutral trend. The MACD of -0.63 indicates Negative momentum. The RSI at 33.64 is Neutral, neither overbought nor oversold. The STOCH value of 58.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ENGN.
enGene Holdings Risk Analysis
enGene Holdings disclosed 84 risk factors in its most recent earnings report. enGene Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
enGene Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $475.55M | -7.92 | -27.09% | ― | ― | -1.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $1.55B | -13.06 | -59.27% | ― | -100.00% | -62.96% | |
45 Neutral | $118.57M | -1.84 | -29.34% | ― | ― | -32.34% | |
45 Neutral | $271.08M | -3.31 | -0.11% | ― | ― | 40.79% | |
43 Neutral | $739.85M | -2.57 | -102.69% | ― | ― | -13.96% | |
42 Neutral | $25.05M | -1.60 | -64.17% | ― | -100.00% | 94.65% |
* Healthcare Sector Average
ENGN
enGene Holdings
1.75
-1.54
-46.81%
TVRD
Tvardi Therapeutics
2.63
-22.96
-89.72%
CAPR
Capricor Therapeutics
26.05
14.11
118.17%
REPL
Replimune Group
8.78
-0.71
-7.48%
IMRX
Immuneering
4.10
1.33
48.01%
CTNM
Contineum Therapeutics, Inc. Class A
12.40
8.75
239.73%
enGene Holdings Corporate Events
Business Operations and StrategyExecutive/Board ChangesFinancial Disclosures
enGene Restructures, Cuts Workforce to Advance Bladder Therapy
Negative
Jun 15, 2026
On June 15, 2026, enGene detailed a sweeping restructuring, including a 50% staff reduction effective June 14, 2026, and halted enrollment in certain LEGEND cohorts to preserve capital as it awaits 12-month durability data and plans a Biologics Li...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
enGene Holdings Shareholders Approve Board and Auditor Slate
Positive
Jun 10, 2026
At its Annual General Meeting held on June 9, 2026, enGene Therapeutics Inc. reported that shareholders representing approximately 83.89% of its 66,989,466 outstanding common shares were present or represented by proxy, underscoring strong investo...
Business Operations and StrategyExecutive/Board ChangesProduct-Related Announcements
enGene Releases Mixed Interim Data from LEGEND Phase 2 Trial
Neutral
May 7, 2026
On May 5, 2026, enGene USA amended and restated the employment agreement with Dr. Hussein Sweiti, effective May 6, 2026, updating his compensation to a $561,750 base salary, a 40% annual bonus opportunity, and continued benefit eligibility. The ne...
Business Operations and StrategyRegulatory Filings and Compliance
enGene Therapeutics Rebrands as Company Nears Commercialization
Positive
Apr 9, 2026
enGene Therapeutics Inc., a clinical-stage, non-viral genetic medicines company focused on high-need diseases such as non-muscle invasive bladder cancer, is advancing its lead gene therapy candidate detalimogene voraplasmid through the Phase 2 LEG...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.